Document is current
Any future updates will be listed below
-
Authors
Peters, Triinu https://orcid.org/0000-0002-7341-2802
Kolar, David https://orcid.org/0000-0002-8649-5467
Föcker, Manuel https://orcid.org/0000-0002-4783-6265
Bühren, Katharina
Dahmen, Brigitte https://orcid.org/0000-0003-3079-7666
Becker, Katja https://orcid.org/0000-0003-4858-5127
Weber, Linda
Correll, Christoph U.
Jaite, Charlotte
Egberts, Karin M. https://orcid.org/0000-0002-0270-0954
Romanos, Marcel https://orcid.org/0000-0001-7628-8299
Ehrlich, Stefan https://orcid.org/0000-0003-2132-4445
Seidel, Maria https://orcid.org/0000-0001-8995-6401
Roessner, Veit https://orcid.org/0000-0002-1873-7081
Fleischhaker, Christian
von Gontard, Alexander https://orcid.org/0000-0002-3579-6200
Hahn, Freia
Huss, Michael
Kaess, Michael
Legenbauer, Tanja https://orcid.org/0000-0002-1580-9991
Renner, Tobias J.
Schulze, Ulrike M. E.
Sinzig, Judith
Wessing, Ida https://orcid.org/0000-0001-8248-6814
Antony, Gisela https://orcid.org/0000-0002-5367-6069
Herpertz-Dahlmann, Beate https://orcid.org/0000-0001-8450-3323
Gradl-Dietsch, Gertraud https://orcid.org/0000-0003-3577-0227
Hebebrand, Johannes https://orcid.org/0000-0001-5364-6073
- License Information
-
More Information
Article History
Received: 1 July 2021
Accepted: 26 November 2021
First Online: 22 December 2021
Change Date: 16 May 2022
Change Type: Update
Change Details: Following the original publication of this article, the funding declaration of the article has been corrected with the addition of the following note: Open Access funding enabled and organized by Projekt DEAL.
Declarations
:
: The ethics committees of all participating universities (n = 14) and local research centers (n = 2) approved the register study. A written informed assent/consent of both patient and at least one legal guardian was available.
: Not applicable.
: Dr. Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of LB Pharma.
